An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Completed
- Conditions
- Colorectal Cancer
- Registration Number
- NCT01609075
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This observational, multicenter, retrospective/prospective study will evaluate the use of Avastin (bevacizumab) in clinical practice in patients with metastatic colorectal cancer. Patients having initiated first-line treatment with a fluoropyrimidine-based chemotherapy and Avastin will be followed for up to 15 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 437
Inclusion Criteria
- Adult patients, >/= 18 years of age
- Metastatic colorectal cancer
- Having initiated first-line treatment with fluoropyrimidine-based chemotherapy plus Avastin between 1. September 2011 and 29. February 2012
- Availability of test fro K-RAS genotyping
Read More
Exclusion Criteria
- Participation in a clinical trial during treatment with Avastin
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients with Avastin treatment discontinuation due to either disease progression or Avastin-related adverse events approximately 15 months
- Secondary Outcome Measures
Name Time Method Proportion of patients with treatment discontinuation due to other causes approximately 15 months Incidence of other causes for treatment discontinuation approximately 15 months Second-line treatments initiated approximately 15 months Progression-free survival (patients with treatment discontinuation due to disease progression or Avastin-related toxicity as compared to patients with treatment discontinuation due to other causes) approximately 15 months